Cost-Effectiveness Opportunities for New Antibiotics
Author:
- 1 January 1994
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 5 (2) , 40-43
Abstract
Antibacterial drugs account for between 6 and 21% of the drug market in various countries, or between 3 and 25% of the total prescriptions. Given the high usage of these agents, they are appropriate candidates for economic appraisal in the near future. It is probable that the marketplace and healthcare reform will give managed care the dominant position in the US healthcare system. Cost-effectiveness analyses of managed care organisations are based on both hospital and outpatient costs, and they are increasingly being aimed at formulary decisions regarding pharmaceuticals. Appropriate outcome parameters, long term follow-up, and phase IV trials to determine costs and outcomes relating to actual clinical use are needed to assess cost-effectiveness. Unbiased pharmacoeconomic research is needed to accurately answer questions on the economic viability of new products, and to avoid scepticism on the part of the purchasers of healthcare. The ultimate challenge for research and development of new antibiotics will be to reconcile the needs of the patient with the economic needs of society, within the cost-effectiveness paradigm.Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of New Anti-Infective Drugs for the Treatment of Urinary Tract InfectionClinical Infectious Diseases, 1992
- Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract InfectionsClinical Infectious Diseases, 1992
- Cost Effectiveness of Once-Daily Oral Antimicrobial TherapyThe Journal of Clinical Pharmacology, 1992
- Pharmacoeconomics of Antibacterial TreatmentPharmacoEconomics, 1992
- The Use of Oral Antibiotics in Daily Clinical PracticeDrugs, 1991
- A Nationwide Survey of Antibiotic Prescribing Patterns and Clinical Outcomes in Patients with Bacterial PneumoniaDICP, 1990
- Epidemiological features and chemotherapy of community-acquired respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 1990
- Treatment of Respiratory Tract Infections with Cephalosporin AntibioticsDrugs, 1987
- Economic costs of respiratory tract infections in the United StatesThe American Journal of Medicine, 1985
- Looking into the crystal ball: can we estimate the lifetime cost of rheumatoid arthritis?1985